NRMHA
National Rmbs Trust 2016-1
๐ฆ๐บ ASX
๐ Overview
๐ Performance
๐ต Cost
๐ค Advanced
๐จโ๐ฉโ๐งโ๐ฆ Community
๐
N/A
Annual Growth
5 years average annual growth
๐ต
$ 500
Minimum Order
Due to regulatory requirements
๐
0
Pearlers Invested
Since January 2020
๐ Overview
Key information
๐ Fund Overview
Class A Frn Mat.20-Dec-2047 Min.Cons.$5Ht Nc
๐ Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
๐๏ธ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out โ๐ต Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out โโฑ๏ธ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out โ๐ต Costs
๐ผ
N/A
Management Fee
Included in unit price, not charged by Pearler
๐ธ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐ธ Net fee calculator๐ค Advanced information
Technical Info
๐ฉโ๐ฉโ๐ฆ Community Insights
How our community is investing
๐ Pearlers invested in NRMHA
0
๐ Total Capital Earnings
N/A
๐ Average investment frequency
N/A
๐ต Average investment amount
N/A
โฐ Last time a customer invested in NRMHA
N/A
NRMHA investor breakdown
๐ต Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
๐ถ Age of investors
18 - 25
26 - 34
35 - 90
๐ Legal gender of investors
Female
Male
Pearlers who invest in NRMHA also invest in...
Want more shares? Try these...
Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Castle Hill, New South Wales. The company went IPO on 2016-08-09. The company is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. The company utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.
๐ Performance (5Yr p.a)
-12.69%
๐ Share price
$0.09 AUD
๐งฌ BIOTECHNOLOGY
NewPeak Metals Ltd. engages in coal and lithium exploration in Argentina, oil and gas in Australia, and gold exploration in U.S. Its projects include cachi gold, san Jorge lithium brine and las openas gold. The company is headquartered in Brisbane, Queensland. The company went IPO on 2011-04-11. The firm has gold exploration assets in three of the mining jurisdictions globally: Finland, Argentina and New Zealand. The company has a suite of gold projects in a region in Finland which hosts three gold mines, Orivesi, Jokisivu and Kaapelinkulma. The Las Openas Gold Project is located in the province of San Juan, with a lease area of approximately 1,462 hectares. The Cachi Gold Project is a Caldera hosted epithermal gold vein system spanning approximately 10 kilometers across and five kilometers in width. The company owns a 75% stake in the Cap Burn Gold Project, in Otago, New Zealand, through an earn-in joint venture with Mineral Rangahau Joint Venture. The company has 100% ownership in several other gold properties, between OceanaGoldโs Macraes Mine in the east, and the Santana-Matakanui Bendigo-Ophir project in the west. The company also has a group of mineral and tungsten exploration assets in Sweden.
๐ Performance (5Yr p.a)
73.33%
๐ Share price
$0.01 AUD
โ๏ธ MINING